- Cerubidine must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration.
- Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m2 in adults, 300 mg/m2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age.
- Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage.
- It is recommended that Cerubidine be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.
- Dosage should be reduced in patients with impaired hepatic or renal function.
CERUBIDINE (Daunorubicin HCl) FOR INJECTION
Cerubidine (daunorubicin hydrochloride) is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of
It is provided as a sterile reddish lyophilized powder in vials for intravenous administration only. Each vial contains 21.4 mg daunorubicin hydrochloride, (equivalent to 20 mg of daunorubicin), and 100 mg mannitol. It is soluble in water when adequately agitated and produces a reddish solution.
Cerubidine in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Published Studies Related to Cerubidine (Daunorubicin)
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. [2011.02.24]
We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin would be as effective as standard-dose idarubicin in remission-induction therapy for newly diagnosed adult patients younger than 65 years of age with acute myeloid leukemia... Thus, high-dose daunorubicin and standard-dose idarubicin were equally effective for the treatment of adult acute myeloid leukemia, achieving a high rate of complete remission and good long-term efficacy.
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2010.02]
OBJECTIVES: The addition of cladribine to the standard regimen consisting of daunorubicin and cytarabine has been reported to increase the efficacy of induction therapy in acute myeloid leukemia (AML). The goal of this study was to determine the effect of this modification on the incidence and spectrum of infectious complications... CONCLUSIONS: The addition of cladribine to standard induction chemotherapy has no impact on the incidence and spectrum of infectious complications in newly diagnosed AML patients. Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. [2009.11.10]
PURPOSE: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)... CONCLUSION: In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.
High-dose daunorubicin in older patients with acute myeloid leukemia. [2009.09.24]
BACKGROUND: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area... CONCLUSIONS: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.) 2009 Massachusetts Medical Society
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. [2005.10.15]
To determine whether MDR1 reversal by the addition of the P-glycoprotein (P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve event-free survival (EFS), 419 untreated patients with acute myeloid leukemia (AML) aged 60 years and older were randomized to receive 2 induction cycles of daunorubicin and cytarabine with or without PSC-833...
Clinical Trials Related to Cerubidine (Daunorubicin)
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML [Completed]
Overall results in the treatment of middle aged adults acute myelogenous leukemia (AML) are
substantially improved in the last decade, with complete remission (CR) rates established to
values of 70 to 80per cent and also encouraging long-term outcome, especially in patients who
can tolerate intensified post remissional treatment strategies. On the contrary, there has
been little progress in the treatment of older patients. In these patients the response rate
generally range between 40 and 60per cent, and overall survival at 2 years is often less than
10 per cent.
Usually, a combination of anthracyclines daunomycin DNR or doxorubicin and cytarabyne Ara-C
has been utilized for the remission-induction treatment, with schedules similar to those
utilized in younger cases, for patients eligible to intensive treatments. Variation of the
dose of DNR has not brought any significant benefit. The EORTC HOVON randomized trial AML9
compared two drugs in induction for previously untreated patients. DNR versus Mithoxantrone
(MTZ). MTZ induction therapy produces a slightly better CR rate than DNR-containing regimen
(47per cent vs 38per cent, P equals 0. 069), without any significant effect on remission
duration and survival. The DFS probability between the two treatment arms was not different.
The median DFS estimates were 39 weeks in both groups. The DFS rate at 5 years was 8per cent.
Also the duration of survival was similar (p equals 0. 23) in the two treatment groups. Median
survival estimates were 36 weeks (DNR) and 39 weeks (MTZ). The percentage of patients still
alive at 5 years were 6per cent and 9per cent respectively.
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome [Recruiting]
The purpose of this study is to see if Panobinostat is safe to give to patients and to
determine the best dose to give in combination with standard cytarabine and daunorubicin
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
This randomized phase II trial is studying how alvocidib, cytarabine, and mitoxantrone
hydrochloride work compared to cytarabine and daunorubicin hydrochloride in treating
patients with newly diagnosed acute myeloid leukemia. Alvocidib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as cytarabine, mitoxantrone hydrochloride, and daunorubicin hydrochloride
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. It is not yet known whether giving alvocidib, cytarabine, and
mitoxantrone hydrochloride is more effective than giving cytarabine and daunorubicin
hydrochloride in treating patients with acute myeloid leukemia
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
The purpose of this research study is to determine if plerixafor can make cells more
sensitive to killing by Cytarabine and Daunorubicin, an anti-cancer drug regimen referred to
as "7+3" that is commonly used in treating acute myeloid leukemia (AML). In this study,
plerixafor is used with treatments Cytarabine and Daunorubicin and with and without
granulocyte-colony stimulating factor (GCSF). Subjects will be monitored to see how well
they tolerate the use of these drugs together and how well they work to treat the leukemia.
The purpose of the study is to find the highest dose of plerixafor and/or recommended phase
2 dose that can be given safely with Cytarabine and Daunorubicin and with and without
granulocyte-colony stimulating factor (GCSF).
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) [Recruiting]
The main purpose of this study are to determine the maximum dose of AT-406 that can be
safely given in combination with cytarabine and daunorubicin to humans. Other purposes are
to determine how the drug is broken down in the body, and to see if there are any molecular
interactions that can help determine how AT-406 works. Side effects will also be studied in
an effort to make sure that this drug is safe to take.
Reports of Suspected Cerubidine (Daunorubicin) Side Effects
Septic Shock (11),
Acute Respiratory Distress Syndrome (9),
Pleural Effusion (7),
Febrile Bone Marrow Aplasia (7),
Generalised Oedema (6),
Bone Marrow Failure (6),
Cytolytic Hepatitis (6), more >>
Page last updated: 2011-12-09